Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages

Takahiko Sato, Daisuke Sugiyama, Jun Koseki, Yasuhiro Kojima, Satomi Hattori, Kazuki Sone, Hitomi Nishinakamura, Tomohiro Ishikawa, Yuichi Ishikawa, T. Kato, Hitoshi Kiyoi, Hiroyoshi NishikawaJCI 2025 · DOI

TL;DR

This study introduces FF-10101, a novel, covalently binding inhibitor of CSF1R, which effectively reduces immunosuppressive tumor-associated macrophages (TAMs) and promotes an anti-tumor immune response. This approach shows promise as a combination therapy with immune checkpoint inhibitors (ICIs) like anti-PD-1, offering a new strategy to overcome resistance in cancer immunotherapy.

What Problem Does This Paper Address?

Cancer immunotherapy, particularly using immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. However, a significant portion of patients do not respond to these therapies, highlighting the urgent need for more effective strategies. A major hurdle to ICI efficacy is the tumor microenvironment (TME), which often contains immunosuppressive cells, notably tumor-associated macrophages (TAMs). These TAMs, particularly the M2-like subtype, actively suppress anti-tumor immunity, promote tumor growth, and contribute to resistance against ICIs. While targeting TAMs is a promising avenue, previous attempts with CSF1R inhibitors have shown limited clinical success. This paper addresses the challenge of effectively targeting TAMs to enhance anti-tumor immunity and overcome ICI resistance.

Methods

The researchers utilized a multi-pronged approach to investigate FF-10101's mechanism and efficacy. Key methods included:

  • In vitro cell culture: Murine bone marrow-derived macrophages (BMDMs), human monocyte-derived macrophages, and the RAW264 macrophage cell line were used to assess FF-10101's direct effects on CSF1R signaling and macrophage polarization.
  • Western Blotting: Used to analyze the phosphorylation status of key signaling molecules (CSF1R, AKT, ERK, STAT1, STAT3, NF-κB) in response to FF-10101 treatment.
  • In vivo animal models: Preclinical studies were conducted using MCA205, MC38, and EMT6 tumor models in mice to evaluate FF-10101's antitumor efficacy, alone and in combination with anti-PD-1 antibodies.
  • Flow Cytometry (FCM): Employed to analyze immune cell populations within the TME, specifically focusing on TAMs and their phenotypes (e.g., FRβ, CD204, PD-L1, PD-L2, Arg-1, iNOS), as well as T cell responses (CD8+, IFN-γ+, TNF-α+, Treg).
  • Bulk RNA Sequencing and Gene Set Enrichment Analysis (GSEA): Used to comprehensively analyze gene expression changes in tumor tissues following FF-10101 treatment, identifying enriched pathways and differentially expressed genes related to macrophage polarization and immune responses.
  • Human Tumor Specimen Analysis: Immune cells were isolated from surgically resected human endometrial cancer specimens and cultured with FF-10101 to assess its effects on human TAMs.
  • Theoretical Conformational Predictions: Molecular docking simulations were used to predict the binding mode of FF-10101 to CSF1R, suggesting a covalent interaction.

Datasets

  • Publicly available scRNA-Seq dataset: Data from the TME of patients with malignant melanoma who received ICI therapy (NCBI GEO GSE120575) was analyzed to identify immune cell clusters and characteristics associated with ICI resistance.
  • Animal model data: Tumor growth curves, immune cell profiling data, and gene expression data were generated from mice inoculated with various tumor cell lines (MCA205, MC38, EMT6, MCA205-SIINFEKL) and treated with FF-10101, anti-PD-1, or combinations.
  • Human endometrial cancer specimens: Primary tumor specimens were used for ex vivo culture and analysis of FF-10101's effects on human TAMs.

Key Insights and Ideas

  • FF-10101's unique covalent binding: The drug's ability to form a covalent bond with CSF1R is hypothesized to be key to its sustained and long-lasting inhibitory activity, differentiating it from other CSF1R inhibitors.
  • Repolarization of TAMs: FF-10101 doesn't just deplete TAMs; it appears to shift the balance from immunosuppressive M2-like TAMs towards immunostimulatory M1-like TAMs, creating a more favorable TME.
  • Synergy with ICIs: The combination of FF-10101 with anti-PD-1 antibodies demonstrated significantly enhanced antitumor effects compared to either treatment alone, suggesting a powerful synergistic mechanism.
  • Broader applicability: FF-10101 showed efficacy even in the EMT6 model, which is known to be refractory to PD-1/PD-L1 blockade, indicating its potential to overcome resistance in diverse tumor types.
  • Dual action on immune cells: Beyond TAMs, FF-10101 also led to a decrease in tolerogenic pDCs, further contributing to an immunostimulatory TME.

Key Results

  • Inhibition of CSF1R signaling: FF-10101 effectively inhibited CSF1R phosphorylation and downstream signaling in macrophages in a dose-dependent manner.
  • Long-lasting inhibitory activity: Unlike other CSF1R inhibitors, FF-10101 maintained its inhibitory activity even after drug removal, suggesting a durable effect.
  • Tumor growth inhibition: FF-10101 significantly inhibited tumor growth in preclinical models (MCA205, MC38).
  • Shift in TAM phenotype: FF-10101 treatment led to an increase in M1-like macrophages and a decrease in M2-like macrophages within the TME.
  • Enhanced CD8+ T cell response: FF-10101 treatment increased tumor antigen-specific CD8+ T cells, including those producing IFN-γ and TNF-α, and improved the CD8+/Treg cell ratio.
  • Reduced immunosuppressive markers on TAMs: FF-10101 treatment significantly reduced PD-L1 and PD-L2 expression on TAMs.
  • Combination therapy efficacy: The combination of FF-10101 and anti-PD-1 mAb showed a significantly stronger antitumor effect than either agent alone, even in a refractory model.
  • Human TAM modulation: FF-10101 treatment reduced PD-L1 expression on TAMs from human endometrial cancer specimens and increased M1-related gene expression.

Limitations and Future Work

  • Sex as a biological variable: The study primarily used female mice, and the relevance of the findings to male mice is unknown. Future studies should investigate sex-specific effects.
  • Compensatory mechanisms: While FF-10101 is effective, the paper acknowledges potential compensatory induction of M-CSF and recruitment of other immunosuppressive cells (PMN-MDSCs, CAFs) as secondary resistance mechanisms. Further research is needed to understand and mitigate these.
  • FLT3 inhibition: FF-10101 is also an FLT3 inhibitor, and its role in the observed effects, particularly the decrease in pDCs, warrants further investigation. The authors suggest that dual inhibition of CSF1R and FLT3 might offer a unique advantage.
  • Patient stratification: The authors emphasize the need for patient stratification based on TME characteristics, particularly abundant immunosuppressive TAMs, to identify optimal candidates for FF-10101 combination therapy.
  • Clinical translation: While promising, FF-10101 is currently in preclinical development. Future work will focus on clinical trials to validate its efficacy and safety in human cancer patients. The development of robust immunomonitoring methods combined with genomic analysis is proposed to guide patient selection and treatment strategies.

Summary updated

Abstract

Tumor-associated macrophages (TAMs) are one of the key immunosuppressive components in the tumor microenvironment (TME) and contribute to tumor development, progression, and resistance to cancer immunotherapy. Several reagents targeting TAMs have been tested in preclinical and clinical studies, but they have had limited success. Here, we show that a unique reagent, FF-10101, exhibited a sustained inhibitory effect against colony-stimulating factor 1 receptor by forming a covalent bond and reduced immunosuppressive TAMs in the TME, which led to strong antitumor immunity. In preclinical animal models, FF-10101 treatment significantly reduced immunosuppressive TAMs and increased antitumor TAMs in the TME. In addition, tumor antigen-specific CD8+ T cells were increased; consequently, tumor growth was significantly inhibited. Moreover, combination treatment with an anti-programmed cell death 1 (anti-PD-1) antibody and FF-10101 exhibited a far stronger antitumor effect than either treatment alone. In human cancer specimens, FF-10101 treatment reduced programmed cell death 1 ligand 1 (PD-L1) expression on TAMs, as observed in animal models. Thus, FF-10101 acts as an immunomodulatory agent that can reduce immunosuppressive TAMs and augment tumor antigen-specific T cell responses, thereby generating an immunostimulatory TME. We propose that FF-10101 is a potential candidate for successful combination cancer immunotherapy with immune checkpoint inhibitors, such as PD-1/PD-L1 blockade.
BibTeX
@inproceedings{sato2025sustained,
  author = {Takahiko Sato and Daisuke Sugiyama and Jun Koseki and Yasuhiro Kojima and Satomi Hattori and Kazuki Sone and Hitomi Nishinakamura and Tomohiro Ishikawa and Yuichi Ishikawa and T. Kato and Hitoshi Kiyoi and Hiroyoshi Nishikawa},
  title = {{Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages}},
  booktitle = {JCI},
  year = {2025},
  doi = {10.1172/jci.insight.178146},
}
Figure